Cape Biologix Technologies

Recombinant proteins from plant-based expression

Cape Biologix Technologies, a subsidiary of Cape Bio Pharms, utilizes plant-based expression platforms to improve the health and well-being of people and animals. The company started in 2020 with the mission to contribute to global biosecurity through manufacturing high quality plant-based proteins that are accessible and economical. Core business is plant-molecular pharming of recombinant proteins. Cape Biologix' transient plant-based expression platform provides a compelling competitive alternative to traditional expression platforms through its superior speed, quality, flexibility, scalability, and sustainability, and does not make use of any animals or animal products

Transient plant-based expression platforms provide unique benefits compared to traditional expression systems such as mammalian cell culture systems. Cape Biologix Technologies’ PtXPro™ technology converts thousands of Nicotiana Benthamiana plants into mini single-use, biodegradable bioreactors. The plants, a distant cousin of tobacco, are infiltrated with Agrobacteria containing a gene of interest cloned into our plant expression vector that results in high yields of recombinant proteins within the leaves. These proteins can be used as research or diagnostic reagents and, under GMP compliance regulations, as therapeutic or vaccine candidates.

Cape Biologix Technologies' catalogue of PtX™ proteins currently includes antibodies and antigens that are catered to research and development projects relating to various disease states including inflammation, HIV, COVID-19, and autoimmune disorders. These high-quality proteins can be used for a variety of applications, including Western Blot, ELISA, and Lateral Flow.

https://capebiologix.com/

Show Product